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Abstract
Heart failure (HF) is a global public health concern that has the potential to reach epidemic
proportions. The gold standard for treating end-stage HF remains heart transplanta‐
tion. Unfortunately, given the scarcity of available organs, alternative means for providing
cardiac support are required. Mechanical circulatory support devices (MCSDs) have the
potential to treat many patients with end-stage HF. They replace some of the mechani‐
cal functions of the failing heart to improve cardiac output and organ perfusion. These
include the intra-aortic balloon pump, extracorporeal membrane oxygenation, ventric‐
ular assist devices, and the total artificial heart. In this chapter, we will discuss a brief
history of MCSD, available devices, indications, patient selection, surgical procedures,
postoperative management, complications, and outcomes.
Keywords: heart failure, intra-aortic balloon pump, extracorporeal membrane oxy‐
genation, ventricular assist device, total artificial heart
1. Introduction
Heart failure (HF) is a global public health concern, affecting 26 million people worldwide at
an estimated cost of $108 billion in 2012. It typically affects the elderly, and both the right heart
and left heart can be involved. In right HF, the right ventricle cannot effectively pump blood to
the lungs. In left HF, which is more common, the left ventricle cannot effectively pump blood
to meet the body’s demands. In our aging world, where 22% of the population is expected to be
over the age of 60 by 2050 [1], HF has the potential to reach epidemic proportions. Although
medications such as beta-blockers, angiotensin-converting enzyme inhibitors, and angioten‐
sin II receptor blockers can alleviate the symptoms of HF and improve mortality [2], the gold
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standard for treating end-stage HF remains heart transplantation. Unfortunately, given the
scarcity of available organs, only about 4500 heart transplantations were performed world‐
wide in patients of all ages in 2013 [3]. The demand for heart transplantations is expected to far
exceed the available supply for the foreseeable future.
Mechanical circulatory support devices (MCSDs) replace some of the mechanical functions of
the failing heart to improve cardiac output and organ perfusion. They have the potential to
treat many patients with end-stage HF who cannot be transplanted either due to lack of
available organs or socioeconomic reasons. Between June 2006 and December 2014, 15,745
patients were implanted with ventricular assist devices (VADs) and the total artificial heart
(TAH) in the United States. These numbers have been rising steadily, from approximately 1000
devices implanted in 2009 to approximately 2500 devices implanted in 2014 in the United States
[4]. Besides the VAD and the TAH, other types of MCSD exist, including the intra-aortic balloon
pump (IABP) and extracorporeal membrane oxygenation (ECMO). The IABP, ECMO, and
VAD can be utilized as a bridge to recovery (BTR). All four types of MCSD can be utilized as
a bridge to transplantation (BTT), whereas only VADs can be utilized as destination therapy
(DT).
In this chapter, we will discuss a brief history of MCSD, available devices, indications, patient
selection, surgical procedures, postoperative management, complications, and outcomes.
1.1. History
MCSDs trace their origin to the early days of cardiac surgery. In 1953, Dr. Gibbon successfully
utilized the heart–lung machine, which he developed over the course of two decades, to repair
an atrial septal defect (ASD) in an 18-year-old woman [5]. This patient did well and was
discharged home. Although his subsequent efforts to utilize the heart–lung machine to close
ASD were met with poor results, secondary to misdiagnosis and bleeding complications, he
laid the foundation for modern-day open-heart surgery with cardiopulmonary bypass [6].
Soon afterwards, it became clear that failure to wean off cardiopulmonary bypass was a
significant problem in the field of cardiac surgery. Dr. Spencer ushered in the use of mechanical
support for postcardiotomy cardiac recovery in 1959. He utilized left atrial–femoral cardio‐
pulmonary bypass to provide temporary cardiac support in postoperative patients. This early
work in mechanical support set the stage for mechanical support for cardiogenic shock [7]. In
1966, Dr. DeBakey performed the first successful implantation of a VAD. He implanted a
paracorporeal VAD from the left atrium to the right subclavian artery in a patient with
cardiogenic shock after a double valve replacement. The patient required mechanical support
for 10 days and ultimately recovered [8]. Dr. Kantrowitz was the first to successfully utilize
the IABP in 1967. His patient was a 45-year-old woman who was in cardiogenic shock
secondary to an acute myocardial infarction. She remained on the IABP for 7 hours and, during
this time, was weaned off all vasopressors ([9]. In 1984, Dr. DeVries reported on the first clinical
use of the TAH. Although the patient ultimately died after 112 days from multiorgan system
failure, the TAH remained functional and uninvolved in any thrombotic or infectious proc‐
esses [10].
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Our modern era of MCSD began in 2001 with the Randomized Evaluation of Mechanical
Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial. This landmark
study compared patients with advanced HF who underwent left ventricular assist device
(LVAD) implantation versus maximal medical therapy. It showed a survival benefit of 52% in
the LVAD group versus only 25% in the medical therapy group at 1 year (p = 0.002). Likewise,
using a variety of quality-of-life questionnaires including the SF-36, Minnesota Living with
HF, and Beck Depression Inventory, the patients who underwent LVAD implantation had a
statistically significant improved quality of life when compared to the medically managed
patients [11]. This pivotal study played a key role in the approval of the LVAD for DT in the
United States in November 2002 [12].
Each of these technological advancements in mechanical support has been monumental.
Equally important was the creation of a national database, the Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS), in the United States. In 2005, this
was developed as a joint venture between the National Heart, Lung, and Blood Institute, the
Food and Drug Administration, the Centers for Medicare and Medicaid Services, and the
University of Alabama at Birmingham. This database serves as a registry for all patients who
have been implanted with VAD and TAH. It collects data from the index hospitalization,
follow-up appointments, and all major adverse events to improve clinical outcomes and
promote research into new devices [4, 13].
2. Devices
2.1. Intra-aortic balloon pump
2.1.1. Background
The IABP is the most frequently utilized MCSD, having been in clinical practice for more than
40 years. When mechanical support is indicated, it is often the first one employed as it could
be readily inserted and has a relatively low complication rate. Upwards of 70,000 patients are
supported annually with the IABP in the United States [14]. It serves as a temporary MCSD
that can be placed quickly at the bedside, in the interventional cardiology suite, or in the
operating room to improve shock and promote organ perfusion.
2.1.2. Basic principles
The IABP results in decreased myocardial oxygen demand and an increase in myocardial
oxygen supply. These physiologic effects are achieved through a reduction in the afterload
and an increase in coronary perfusion [15]. The IABP functions by reducing left ventricular
afterload, which leads to a decrease in left ventricular wall stress. Since wall stress is propor‐
tional to oxygen consumption, this reduction in afterload and wall stress results in decreased
myocardial oxygen consumption. In addition, the IABP increases aortic diastolic pressures.
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Since the coronary arteries are perfused during diastole, this increase in aortic diastolic
pressures leads to increased coronary perfusion and thus myocardial oxygen supply [16, 17].
The combined physiologic effects of afterload reduction and augmented coronary perfusion
lead to an improvement in cardiac output.
Figure 1. IABP Console (Image courtesy of Teleflex.com).
The sequential inflation and deflation of the IABP is synchronized to the electrocardiogram
(EKG), pacemaker, or to the arterial pressure tracing. This results in counterpulsation and the
various hemodynamic changes that are observed. IABP inflation is timed to coincide with the
closure of the aortic valve. As seen on the aortic pressure tracing, this coincides with the dicrotic
notch. Alternatively, it is timed to coincide with the T-wave of the EKG. With counterpulsation,
the IABP rapidly inflates. This inflation increases the intra-aortic pressures and displaces a
volume of blood equivalent to the volume of the balloon (usually 30–50 mL in adults, 2.5–25
mL in children) away from the balloon. This results in increased coronary perfusion.
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Figure 2. IABP Screen with EKG and aortic pressure tracing (Image courtesy of Teleflex.com).
The second phase of the counterpulsation occurs with deflation of the IABP. Deflation is timed
to occur with the onset of the R-wave, or alternatively before the start of systole. Deflation
occurs as late as possible, in order to maintain the increased aortic diastolic pressures. It is also
timed to occur rapidly, which results in a vacuum effect that leads to a reduction in the afterload
by movement of blood toward the balloon [18].
There are several factors that influence the efficacy of the IABP, including heart rate, rhythm,
balloon volume, proximity to the aortic valve, and aortic compliance. As the heart rate
increases, the amount of time the heart spends in diastole decreases. Thus, the IABP is less
likely to function efficiently with tachycardia, since there would be less diastolic coronary flow
augmentation. The optimal rate reported in the literature is from 80 to 110 beats/minute [19].
In addition, having a normal sinus rhythm allows for readily identifiable waves on EKG or
the aortic pressure tracing, which improves the performance of the IABP. Since the balloon
size is proportional to the amount of blood displaced, a larger balloon allows for increased
coronary perfusion and a greater reduction in afterload. In addition, the proximity of the IABP
to the aortic valve affects diastolic augmentation of coronary perfusion. There is greater
diastolic augmentation when the balloon is positioned closer to the aortic valve. Finally, aortic
compliance affects the function of the IABP. Increased aortic compliance, which is seen in
younger patients, results in a decrease in diastolic augmentation [18, 20].
2.1.3. Components and insertion
The IABP system is composed of a dual lumen catheter, with the inner lumen serving to
monitor aortic pressures and the outer lumen connected to a polyethylene balloon that inflates
and deflates. It is also composed of a pump console that controls the inflation and deflation of
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the balloon. The catheters are available in a variety of sizes, depending on the patient’s height.
Helium gas is utilized to inflate the balloon, since it has a low density and rapidly transfers
from the console to the balloon. In addition, helium is inert and could be rapidly absorbed into
the blood stream in the event the balloon ruptures.
The IABP can be placed via both percutaneous and open surgical techniques. In the percuta‐
neous technique, the common femoral artery is punctured with an introducer needle. Using
the modified Seldinger technique, a guidewire is inserted and then the IABP catheter is inserted
over the wire. The catheter is then positioned about 1–2 cm distal to the left subclavian artery
and confirmed with fluoroscopy or chest roentgenogram [18]. Care has to be exercised to
prevent obstruction of the left subclavian artery and left carotid artery by a highly placed IABP.
Care also has to be exercised to avoid placing the IABP too low, as it could occlude mesenteric
and the renal arteries.
Alternatively, the IABP can be placed via open surgical techniques. This is typically reserved
for patients with severe peripheral vascular disease (PVD) affecting the distal aorta, iliac
arteries, or femoral arteries. In such cases, placement of an IABP can lead to critical limb
ischemia. For these patients, the IABP can be inserted into the ascending aorta, aortic arch,
common iliac artery, subclavian artery, axillary artery, and brachial artery [21].
2.1.4. Indications and contraindications
The indications for the IABP include postcardiotomy syndrome, prophylactic support for high-
risk percutaneous coronary interventions, myocardial infarction or its mechanical complica‐
tions, unstable angina, cardiogenic shock, and as a bridge to heart transplantation. The
Benchmark Registry, a multi-institutional study with nearly 17,000 patients, investigated the
patient demographics, outcomes, and complications of the IABP. They found that the indica‐
tions for the IABP were most frequently hemodynamic support during or after cardiac
catheterization (21%), cardiogenic shock (19%), and weaning from cardiopulmonary bypass
(16%) [22].
There are several important contraindications to using the IABP. These include aortic regur‐
gitation, since the IABP would result in increased regurgitation during diastolic augmentation.
In addition, severe aortic diseases, such as aneurysm or aortic dissection, are a contraindica‐
tion. In this setting, the placement of an IABP could result in aortic rupture or extension of the
dissection. Placing them in the femoral region is contraindicated in patients with known severe
PVD [18, 23].
The authors believe the IABP should be the first MCSD that should be placed for typical
cardiogenic shock, when no obvious contraindications exist. Despite the interpretation of the
controversial IABP-Shock II trial, which showed that the IABP did not lead to a reduction in
12-month all-cause mortality in patients undergoing early revascularization for myocardial
infarction complicated by cardiogenic shock [24], we believe the IABP should be the first to be
placed for cardiogenic shock. We believe this for a number of reasons, including its availability
at most hospitals, the ability to initiate its use quickly, and the ability to upgrade it to a more
advanced MCSD if the cardiogenic shock remains poorly addressed.
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2.1.5. Weaning and removal
Little data exists on how to wean patients off the IABP with minimal hemodynamic conse‐
quences. Generally, weaning is performed in one of two ways: rate reduction or volume
deflation. In the first method, the ventricular assist rate is gradually reduced from full support
of every beat (1:1) to cardiac support every other beat (1:2) to finally cardiac support every
three beats (1:3). Once the patient demonstrates that he can tolerate this wean, the IABP is
discontinued. The IABP can also be weaned by maintaining a ventricular rate of 1:1 and
deflating the balloon over several hours. This leads to a decrease in the counterpulsation and
a decrease in diastolic augmentation [25, 26]. There are limited studies in the literature that
have assessed which weaning method is superior. Onorati et al. [26] showed that weaning
using volume deflation led to improved hemodynamic and metabolic parameters in their
study.
Once the patient has demonstrated that he can tolerate being weaned, the IABP is removed.
The removal of percutaneously placed IABP can be performed at the bedside. After prepping
the femoral artery entry site, the balloon catheter is disconnected from the console. It is then
completely deflated and the catheter is removed. Retrograde bleeding is first allowed, which
enables blood clots to flush into the wound. This potentially prevents distal embolization of
blood clots. After this, antegrade flushing is allowed, to once again prevent distal embolization
of blood clots. Finally, the puncture site in the femoral artery is compressed and pressure is
maintained for about 30 minutes. Inadvertent placement of the IABP above the inguinal
ligament can result in a retroperitoneal bleed, while poor technique at the time of removal can
result in a femoral artery pseudoaneurysm and distal embolization with leg ischemia.
2.1.6. Complications
The overall complication rate has been reported to be low. The Benchmark Registry found that
the incidence of all complications to be 7%. This study found that severe complications
occurred in 2.8% of the patients. Severe complications were defined as severe bleeding (with
hemodynamic instability requiring transfusions or surgical interventions), major limb
ischemia (with loss of pulse or sensation or the presence of pallor), balloon rupture, or in-
hospital mortality related to the IABP. Multivariate logistic regression analysis identified
several predictors of major complication, including female gender, PVD, body surface area
<1.65 m2, and age >75 years [22].
Additional complications include renal artery occlusion and renal failure if the IABP is placed
too distally. By manipulating the aorta with the guidewire and catheter, there is always the
possibility of distal embolism, resulting in bowel ischemia or lower extremity ischemia.
In the Benchmark Registry, the incidence of balloon rupture was found to be 1% [22]. Balloon
rupture usually could be detected by the presence of blood either in the IABP driveline or in
console alarms. Balloon rupture is thought to occur secondary to abrasive contact between the
balloon and atherosclerotic plaque in the aorta. It necessitates the immediate removal of the
IABP to prevent thrombus formation around the balloon and distal embolization.
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2.2. Extracorporeal membrane oxygenation
2.2.1. Background
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is another modality for
short-term mechanical support in patients with HF refractory to medical management. Initial
reports of its success were described by Baffes et al. in the 1970s in the pediatric population
[27]. Since that time, its applications have been broadened to include adult patients with
reversible cardiogenic shock and as a bridge to VAD implantation or transplantation. It can
also serve as rescue therapy in patients with cardiopulmonary arrest [28]. Chen et al. showed
that VA-ECMO could be utilized in patients in cardiopulmonary arrest after 10 minutes of
unsuccessful advanced cardiovascular life support. It was shown that VA-ECMO could extend
the duration of cardiopulmonary resuscitation (CPR) with 50% survival with acceptable
neurologic status at 30 minutes [29]. A recent meta-analysis showed ECMO in adult patients
in cardiac arrest had statistically significant improved outcomes if they were younger (age 17–
41) and had a shorter duration of ECMO support (0.9–2.3 days) [30].
Figure 3. ECMO circuit with pump and heater.
2.2.2. Basic principles
VA-ECMO is a form of advanced cardiopulmonary life support which functions essentially
like cardiopulmonary bypass. Blood is drained from a central vein, circulated in the ECMO
circuit, and then returned to the arterial system. In neonates and children, the carotid artery is
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typically accessed for arterial cannulation. In adults, arterial cannulation is obtained via the
femoral, axillary, or carotid artery. Venous access is obtained via the femoral or internal jugular
vein. It provides cardiac support by augmenting cardiac output and respiratory support by
assisting in gas exchange. VA-ECMO can be utilized for a period of days to weeks [31].
2.2.3. Components and insertion
The ECMO circuit consists of a blood pump and membrane oxygenator with a heat exchanger
connected to the VA-ECMO cannulas. The membrane oxygenator has a membrane that readily
allows diffusion of oxygen and carbon dioxide across it. Oxygen can be added to the system
by increasing the amount of oxygen supplied to the oxygenator. Carbon dioxide can be
adjusted by changing the gas flow rate or the “sweep.” The heat exchange helps maintain
normothermia, as heat is readily lost through the circuit.
Figure 4. Biventricular assist devices (Centrimag).
Cannulation insertion techniques include both percutaneous and open surgical approaches.
Percutaneous cannulas are inserted using the Seldinger technique and can be placed readily
at the bedside. After gaining access, the vessels are serially dilated and the cannula is then
placed over the guidewire. The patient requires full anticoagulation with heparin. The femoral
vessels are most commonly used in the adult. For adults, the arterial cannula size ranges
Mechanical Circulatory Support Devices
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between 12 French (Fr) and 22 Fr and the venous cannula size ranges between 18 Fr and 28 Fr.
An arterial perfusion cannula (typically 5–8 Fr) can also be added to perfuse the lower
extremity, as lower extremity ischemia is a source of significant morbidity and mortality. A
similar venous drainage line can be placed to drain blood from the lower extremity, as venous
outflow obstruction too can lead to lower extremity ischemia [32].
Figure 5. Biventricular assist devices (Centrimag).
Our institutional practice has been to use a 15 Fr arterial cannula placed via the Seldinger
technique for patients who need modest support. This allows us to decannulate the patient at
bedside without needing to perform a cutdown. When patients require more robust cardiac
support, we use larger cannulas, typically 17–21 Fr. We prefer to perform open insertion when
these larger cannulas are required. It also requires decannulation in the operating room. We
prefer to initiate VA-ECMO in the operating room whenever possible, provided the patient is
stable enough to tolerate transport and waiting for operating room availability. Distal perfu‐
sion cannulas should be routinely placed. If they are not utilized, the lower extremity has to
be monitored for ischemia. There has to be a low threshold for insertion of a distal perfusion
cannula, as the morbidity and mortality of an ischemic limb in a patient on VA-ECMO can be
catastrophic. We perform central VA-ECMO on our patients who have postcardiotomy
cardiogenic shock or in patients who need robust support. We usually use 18–22 Fr arterial
cannulas placed in the ascending aorta and 31–40 Fr venous cannulas placed in the right
atrium.
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2.2.4. Indications and contraindications
The indications for VA-ECMO in adult patients are cardiogenic shock from a variety of causes
including acute myocardial infarction, myocarditis, drug toxicity, and pulmonary embolism.
It also includes peripartum cardiomyopathy, decompensated chronic HF, postcardiotomy
shock, and as a bridge to VAD implantation or heart transplantation. Typically, patients have
low cardiac index (<2 L/min/m2) and hypotension (systolic blood pressure <90 mmHg) despite
inotropic agents, IABP, and adequate volume resuscitation [33]. Advantages of VA-ECMO
over temporary VAD include ease of insertion bedside and not needing to transport a
hemodynamically unstable patient to the operating room.
Absolute contraindications to ECMO include patients who are not candidates for transplan‐
tation or VAD implantation, disseminated malignancy, unwitnessed cardiac arrest, end-stage
organ dysfunction, non-compliance, and patients with prolonged CPR without adequate tissue
perfusion. Relative contraindications include advanced age, obesity, and contraindications to
anticoagulation [33, 34].
2.2.5. Management
There are no randomized trials to date that have validated management guidelines. However,
there are general management strategies that are implemented at most institutions. Such
strategy is geared toward minimizing multiorgan system dysfunction. The complex manage‐
ment of a patient on VA-ECMO requires coordination and communication between the
cardiothoracic surgeon, critical care intensivist, perfusionist, nurses, and ancillary staff.
For the respiratory system, successful management requires aggressive pulmonary toileting.
This necessitates frequent endotracheal suctioning and possible bronchoscopy, positional
changes, nebulizers, and chest roentgenogram. The fraction of inspired oxygen (FIO2) is
minimized in order to lessen oxygen toxicity. In order to lessen atelectasis, increased positive
end-expiratory pressures (PEEPs) is often implemented [33]. Schmidt et al. showed that higher
PEEP during the first 3 days on ECMO led to improved survival [35].
Successful cardiovascular support requires maintaining perfusion and aggressive volume
resuscitation during the first few days on ECMO. Since ECMO promotes release of cytokines
and a generalized systemic inflammatory response syndrome, adequate volume resuscitation
with crystalloid or colloid is paramount. In addition, inotropic support is often required as the
heart recovers.
The management of the renal system is often complex in the ECMO patient. Nearly 70–85% of
patients on ECMO develop acute kidney injury (AKI) [36]. The first 2 days on ECMO usually
require aggressive fluid resuscitation and is associated with oliguria. The diuretic phase
usually begins after 2 days. Frequently, diuretics are utilized to improve mobilization of
extravascular fluid. If AKI does not improve, renal replacement therapy often becomes
indicated. However, the requirement for dialysis carries a significant mortality risk. Kielstein
et al. showed that patients on ECMO who required dialysis had a 3-month survival rate of 17%
while those on ECMO who did not required dialysis had a 3-month survival rate of 53% (p =
0.001). They also showed that duration of dialysis was associated with increased mortality [37].
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Management of the gastrointestinal system and nutrition focuses on maintaining the integrity
of the gastrointestinal mucosa, in order to lessen translocation of bacteria. This is accomplished
with proton pump inhibitors or histamine blockers and enteral nutrition when possible [38].
However, parenteral nutrition is often required to supplement nutrition, as enteral nutrition
is often interrupted. A recent study by Ridley et al. showed that enteral nutrition was inter‐
rupted for a median of 8 hours on 53% of the days. This was secondary to high gastric residual
volume or fasting for a procedure or diagnostic test [39].
Neurologic complications are very common with ECMO and the clinician needs to have a low
threshold to pursue imaging to rule out intracranial hemorrhage and acute stroke. Recently,
all patients who received ECMO between 2001 and 2011 were selected from the Nationwide
Inpatient Sample. Neurologic complications included acute ischemic stroke, intracranial
hemorrhage, and seizures were evaluated. Of the 23,951 patients included in the study, 10.9%
of patients suffered seizures, 4.1% suffered strokes, and 3.6% suffered intracranial hemorrhage.
Patients who suffered intracranial hemorrhage were found to have a higher mortality rate,
length of stay, and discharge to a long-term facility than those who did not have intracranial
hemorrhage. Similarly, patients who suffered acute ischemic stroke had higher rates of
discharge to long-term facilities and length of stay than patients who did not have an acute
ischemic stroke. No difference in outcomes was found between those who had seizures and
those who did not [40].
2.2.6. Weaning
Currently, there is a lack of established guidelines on weaning patients from VA-ECMO.
Generally, patients have to demonstrate hemodynamic stability, recovery of organ dysfunc‐
tion, resolution of pulmonary edema, and be in a euvolemic state. Echocardiogram is an
invaluable tool for assessing cardiac recovery. Different institutions utilize different weaning
parameters. Generally, weaning is accomplished once echocardiogram shows improvement
of cardiac function. ECMO support is then gradually weaned, with flows reduced to 50% and
then 25%. If the patient tolerates this, the circuit is then clamped between 30 minutes to 4 hours.
The cannulas must be flushed with heparinized saline frequently to prevent thrombosis. Once
the patient tolerates this, decannulation can be performed at bedside or in the operating room
for large cannulas [41].
2.2.7. Complications
The most common complications in patients on VA-ECMO are bleeding and thrombosis.
Bleeding requiring surgical treatment has been reported to occur in nearly 34% of patients on
VA-ECMO [42]. It is a major concern for patients on VA-ECMO since the patients are antico‐
agulated with heparin and have platelet consumption and dysfunction [33]. Anticoagulation
is a critical component to prevent circuit thrombosis, although there are no clear guidelines
for standardized goals. However, most institutions use heparin with an activated partial
thromboplastin time (aPTT) of 60–80 seconds. There is also an increased risk of disseminated
intravascular coagulation (DIC) and heparin-induced thrombocytopenia (HIT). HIT mandates
anticoagulation with a non-heparin-based agent. Available medications include bivalirudin
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and argatroban. Additional complications include infection, neurological complications, and
limb ischemia. Limb ischemia is a function of cannula size and positioning in relation to the
patient’s vasculature. Reperfusion cannulas to perfuse distal to the entry site have decreased
the risk of this complication [32, 43].
2.3. Ventricular assist devices
2.3.1. Background
VAD technology has advanced rapidly since the landmark REMATCH trial, which demon‐
strated survival and quality of life improvement in patients who underwent implantation of
an LVAD compared to patients receiving maximal medical therapy. It also highlighted several
limitations of pulsatile devices, namely device failure and thromboembolism [11]. Advance‐
ment in technology has led to the development of continuous-flow devices. These devices have
been associated with significantly improved survival free from stroke and device failure at 2
years, when compared to pulsatile devices [44]. Overall survival with the current continuous-
flow VADS in use today is reported to be 80% at 1 year and 70% at 2 years post implantation [4].
Figure 6. Paracorporeal ventricular assist devices (Reprinted with the permission of Thoratec Corporation).
Most frequently, VADs are implanted to assist the left ventricle. The inflow cannula is inserted
into the left ventricle and the outflow cannula is inserted into the ascending or descending
aorta. They can also provide right ventricular and biventricular support. In a right ventricular
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assist device (RVAD), the inflow cannula is inserted into the right atrium or right ventricle and
the outflow cannula is inserted into the pulmonary artery.
Figure 7. HeartMate XVE (left) and HeartMate II (right) (Reprinted with the permission of Thoratec Corporation).
Figure 8. HeartMate II cross-section view with internal rotor (Reprinted with the permission of Thoratec Corporation).
VADs can be classified based on how they function mechanically. The first-generation VADs
rely on pulsatile-flow technology. These VADs contain one-way valves and a flexible pumping
chamber, which is compressed by an electric motor or pneumatic pressure. This forces blood
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into the circulation. These patients will have a palpable pulse and a measurable blood pressure.
The second-generation VADs are continuous axial flow devices while the third-generation
VADs are continuous, centrifugal flow devices. These nonpulsatile, continuous-flow devices
have internal rotors, which propel blood continuously. These patients have either weak,
irregular pulses or non-palpable pulses.
In addition, VADs can provide both short-term and long-term circulatory support. Those
designed for short-term circulatory support serve to restore organ perfusion quickly to relieve
organ ischemia. They are used for BTR and BTT. These are non-implantable and provide
support for days to weeks. Long-term VADs are implantable and are used for DT or BTT. The
majority of VAD are implanted surgically. However, there are devices currently available that
can be placed percutaneously.
Figure 9. HeartMate II (Reprinted with the permission of Thoratec Corporation).
VADS are preload dependent and afterload sensitive. They can function independently of the
EKG and most require anticoagulation. Generally, these devices are prone to infection,
bleeding, hemolysis, thrombosis, cerebrovascular accidents, and mechanical malfunction. In
addition, right ventricular dysfunction is a known complication of LVAD insertion, as the right
ventricle has to increase its output to match the left heart and LVAD.
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Figure 10. HeartMate 3 (Reprinted with the permission of Thoratec Corporation).
2.3.2. Indications for VAD
As mentioned earlier, indications for VAD can be divided into three main groups: BTR, BTT,
and DT. Mechanical support with a VAD is used as a BTR in patients with acute decompen‐
sated HF. These patients typically have reversible causes of HF, such as postcardiotomy
syndrome, medicine-induced cardiomyopathy, postpartum cardiomyopathy, and viral
myocarditis. A retrospective study showed that patients who have acute fulminant myocar‐
ditis that progressed rapidly (median of 7 days from onset of symptoms to VAD implantation)
had a greater likelihood of recovery of cardiac function and VAD explantation than patients
who had a more indolent presentation (median of 22 days between onset of symptoms to VAD
implantation). Those with a more indolent presentation were more likely to progress to
needing a heart transplantation [45].
BTT remains the most common indication for MCSD. The Seventh INTERMACS report
showed that implantation of VADs as BTT was about 51% in 2014 [4]. VADs allow patients
with advanced HF to become healthier while awaiting heart transplantation. It has been shown
that patients who receive a VAD as a BTT have improved functional capacity and quality of
life [46].
DT refers to the use of VAD as definitive treatment for patients who do not qualify for heart
transplantation. The Seventh INTERMACS report showed that implantation of VADs as DT
has been steadily rising. In the year 2014, 45.7% of all VADs implanted in the United States
have been for DT, up from 43.6% in 2013. This is in stark contrast to the 2008–2011 time period,
when only 28.6% of all VADs implanted were for DT [4].
A fourth group, bridge to decision (BTD), is a new designation for those patients whose
candidacy for heart transplantation or permanent VAD is still not determined, either due to
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medical or socioeconomic reasons. A recent study investigating the CentriMag VAD, an
external continuous-flow device, as BTD therapy in patients with refractory cardiogenic shock
demonstrated survival of 69.2% at 30 days and survival of 48.6% at 1 year. This study showed
that 30% of patients had sufficient myocardial recovery to allow explantation of the VAD.
Another 15% of patients progressed to needing a permanent VAD and 18% of patients required
heart transplantations [47].
2.3.3. Short-term VADs
Short-term VADs are available as pulsatile and nonpulsatile devices. The short-term pulsatile
device includes the first-generation Abiomed BVS 5000 and the second-generation Abiomed
AB 5000, which allows the patient to be more mobile. These are paracorporeal devices that can
provide left ventricular, right ventricular, or biventricular support for several weeks. In a
retrospective single institution review, the Abiomed BVS 5000 was inserted for precardiotomy
cardiogenic shock in 18 patients and for postcardiotomy cardiogenic shock in 53 patients. Of
these, 62% of the patients survived, with 41% of patients being successfully weaned after
myocardial recovery, 11% receiving a long-term LVAD, and 10% receiving a heart transplan‐
tation [48]. Similar to other VADs, patients require anticoagulation while being supported by
this device.
Nonpulsatile short-term devices that could provide univentricular and biventricular support
include the Impella and TandemHeart. These devices require anticoagulation and could be
readily placed in the interventional cardiology suite for acute HF. The Impella LP 2.5 is a
catheter-based VAD that is inserted via the femoral artery. It is passed into the aorta, through
the aortic valve, and into the left ventricle. The catheter has an inlet at its tip and an outlet more
proximally. This device functions by pumping blood through the inlet located in the left
ventricle and into the outlet located in the ascending aorta. This lessens the amount of work
the left ventricle has to perform and augments cardiac output. The Impella LP 5.0 works
similarly but is larger and requires a formal aortotomy or femoral artery cutdown.
However, the TandemHeart consists of a centrifugal pump and a cannula placed through the
femoral vein and guided into the right atrium. From there, the cannula is placed transeptally
into the left atrium. A femoral artery cannula is also placed and blood from the left atrium is
passed into the femoral artery, thereby bypassing the left ventricle [49]. In the largest study of
its kind, Patel et al. showed that percutaneous VADs such as the TandemHeart and Impella
led to a statistically significant reduction in mortality when compared to the IABP in patients
undergoing percutaneous coronary intervention [50].
2.3.4. Long-term VADs
Long-term VADS can be divided into three generations. The first-generation VADs rely on
pulsatile flow technology. It includes the HeartMate XVE, a VAD that has been extensively
studied. In fact, it was this device that was studied in the seminal REMATCH trial. It has a
textured inner surface, which promotes pseudoneointimal lining formation throughout the
pump. Consequently, anticoagulation is not necessary and these patients often only receive
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antiplatelet therapy in the form of aspirin. The incidence of neurologic events remains low
with this device. A small retrospective study with 21 patients showed no strokes or transient
ischemic attacks during the average of 531 days of LVAD support. Only two of these patients
developed metabolic encephalopathy, which resolved [51]. Major limitations of this device
include increased incidence of infection, device malfunction, and its large size, which makes
implantation into patients of a body surface area of less than 1.5 m2 not feasible. Other first-
generation devices include the Novacor, EXCOR, Thoratec IVAD, and Thoratec PVAD.
The second-generation VAD rely on a rotatory axial pump design. These are typically much
smaller than the first-generation VADs because of the nonpulsatile flow design. By eliminat‐
ing pulsatile flow, the need for having valves and chambers was eliminated. In addition, there
are less moving parts leading to less hardware dysfunction. They also require less energy
consumption.  This  group  includes  the  HeartMate  II,  MicroMed  DeBakey  (now  Relian‐
tHeart), and Jarvik 2000. The HeartMate II has been extensively studied and has revolution‐
ized the field of VAD. It was investigated against the HeartMate XVE by Slaughter et al. In
their  study,  they  showed that  continuous  flow LVAD had a  statistically  significant  im‐
proved  probability  of  survival  free  from  stroke  and  device  failure,  when  compared  to
pulsatile devices. In addition, the HeartMate II had actuarial survival rates of 68% at 1 year,
compared to 55% for the HeartMate XVE. The survival benefit extended to 2 years, with 58%
survival in the HearMate II cohort and 24% in the HeartMate XVE cohort [44].
The third-generation VAD also relies on continuous flow technology. However, instead of
having a rotor in contact with blood, which results in hemolysis, there is a hydrodynamic or
magnetic levitation component, which eliminates contact with blood. These include the
DuraHeart, HeartMate 3, HeartWare, Evaheart, and INCOR. These remain investigational and
in clinical trials in the United States. In Europe, several studies have already been conducted.
A retrospective study from Italy reviewed the INCOR VAD in 42 patients. In their cohort,
Iacovoni et al. showed survival of 74% at 1 year and 60% at 2 years. The most frequent adverse
events included driveline infection, stroke, sepsis, and right HF. No episodes of pump
thrombosis or gastrointestinal bleeding occurred [52].
2.3.5. Operative technique
Typically, VADs are placed via a median sternotomy and require cardiopulmonary bypass. A
preperitoneal pocket is created to implant the device. Meticulous hemostasis is necessary since
postoperative hematomas in the device pocket can predispose to infections. Alternatively, with
the increasing miniaturization of the VADs, they can be placed within the pericardium.
With some of the newer models, implantation is possible via a thoracotomy incision and
without cardiopulmonary bypass [53, 54].
2.3.6. Postoperative management
Postoperative care after VAD implantation requires a multidisciplinary approach to care.
However, special attention has to be paid to blood pressure monitoring, anticoagulation, and
right ventricular function. While arterial lines are in place, blood pressure can be titrated to
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mean arterial pressure (MAP) of 70–80 mmHg. Once invasive lines are discontinued, a Doppler
probe and sphygmomanometer can be utilized to measure blood pressure. Antiplatelet
therapy and anticoagulation is started within a few days postoperatively, once risks of bleeding
and coagulopathy have subsided. Antiplatelet therapy is started with aspirin. Anticoagulation
is started with a heparin drip and the transitioned to oral warfarin. Alternatively, starting
warfarin without a heparin bridge has been reported. It has been shown that such management
reduces the need for blood transfusions without increasing risks for short-term thrombosis or
thromboembolic events [55]. The right ventricle is supported with the use of inotropes and
pulmonary vasodilators such as nitric oxide, prostaglandins, and milrinone. Despite maximal
medical therapy, if central venous pressures remain consistently above 20 mmHg and the
cardiac index remains below 2 L/min/m2, implantation with a temporary RVAD may be
indicated.
2.4. Total artificial heart
2.4.1. Background
The TAH is a mechanical support device, which has not yet gained widespread acceptance.
Only 66 were implanted in the United States in 2013 [4]. It provides pulsatile biventricular
support and is pneumatically powered. With this device, the right and left ventricle and all
the heart valves are removed. The removal of the native ventricles and valves eliminates many
of the problems seen with LVAD or biventricular support, namely right HF, valvular regur‐
gitation, and arrhythmias. The TAH is connected directly to the atria. It is currently approved
Figure 11. Total Artificial Heart with battery pack (Image courtesy of Syncardia.com).
Mechanical Circulatory Support Devices
http://dx.doi.org/10.5772/62875
275
for support for biventricular HF as a BTT [56]. It is available as the SynCardia TAH and
AbioCor.
2.4.2. Indications
The main indication for the TAH is as a BTT for biventricular failure. It can be used in patients
who have contraindications to LVAD and biventricular assist devices implantation. Such
patients include those infiltrative or restrictive cardiomyopathies, aortic regurgitation, severe
cardiac arrhythmias, and left ventricular thrombus.
In a study by Copeland et al., 81 patients were implanted with the TAH as a BTT. Of these, the
rate of survival to transplantation was 79%. The overall 1-year survival for patients implanted
with the TAH was 70%. In those patients who received heart transplantation after a TAH, the
1-year survival was 86% and the 5-year survival was 64% [57].
2.4.3. Limitations and complications
Major limitations to its use include its large size, requiring the patient to have a body surface
area of at least 1.7 m2. It also requires extensive surgery to remove both of the ventricles and
all the valves. It is also fraught with complications including infection, postoperative bleeding,
and thromboembolic events [58].
Figure 12. Total Artificial Heart (Image courtesy of Syncardia.com).
3. Conclusion
With the increase in HF and the lack of available hearts for transplantation, MCSDs will
continue to play a greater role as a BTR, BTT, or DT.
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